$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000082787118000003 Filed on February 26, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$46.79M	$63.02M	$50.11M
YoY Change	-42.34%	66.58%	22.46%
Cost Of Revenue	$13.71M	$4.815M	$8.910M
YoY Change	-27.15%	-53.81%	-22.34%
Gross Profit	$33.08M	$58.21M	$41.20M
YoY Change	-46.92%	112.37%	39.92%
Gross Profit Margin	70.71%	92.36%	82.22%
Selling, General & Admin	$13.32M	$16.67M	$23.28M
YoY Change	-23.4%	42.95%	94.16%
% of Gross Profit	40.27%	28.64%	56.51%
Research & Development	$9.440M	$8.954M	$6.684M
YoY Change	-43.3%	179.2%	75.94%
% of Gross Profit	28.54%	15.38%	16.22%
Depreciation & Amortization	$950.0K	$950.0K	$940.0K
YoY Change	41.79%	163.89%	193.75%
% of Gross Profit	2.87%	1.63%	2.28%
Operating Expenses	$22.63M	$38.07M	$44.21M
YoY Change	-33.52%	49.15%	62.15%
Operating Profit	$10.44M	$24.95M	$5.902M
YoY Change	-63.08%	102.71%	-56.78%
Interest Expense	-$500.0K	$527.0K	$40.00K
YoY Change	-5100.0%	17466.67%	1233.33%
% of Operating Profit	-4.79%	2.11%	0.68%
Other Income/Expense, Net		-$492.0K	-$26.00K
YoY Change		-2239.13%	-196.3%
Pretax Income	$9.940M	$24.46M	$5.876M
YoY Change	-64.86%	98.35%	-57.06%
Income Tax	-$2.550M	$9.027M	$1.373M
% Of Pretax Income	-25.65%	36.91%	23.37%
Net Earnings	$9.090M	$15.43M	$4.503M
YoY Change	-84.14%	29.11%	-65.62%
Net Earnings / Revenue	19.43%	24.49%	8.99%
Basic Earnings Per Share	$0.61	$1.03	$0.30
Diluted Earnings Per Share	$0.58	$0.98	$0.28
COMMON SHARES
Basic Shares Outstanding	14.92M shares	15.05M shares	15.22M shares
Diluted Shares Outstanding		15.76M shares	16.10M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.7M	$97.50M	$55.40M
YoY Change	117.23%	64.42%	-26.72%
Cash & Equivalents	$114.7M	$97.55M	$55.39M
Short-Term Investments
Other Short-Term Assets	$561.0K	$850.0K	$688.0K
YoY Change	58.03%	99.53%	109.76%
Inventory	$5.118M	$4.878M	$3.587M
Prepaid Expenses
Receivables	$53.82M	$71.60M	$53.23M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$188.7M	$182.2M	$123.9M
YoY Change	72.94%	53.01%	-8.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.820M	$4.365M	$3.768M
YoY Change	105.67%	54.4%	33.95%
Goodwill	$39.74M	$39.74M	$39.74M
YoY Change	0.0%
Intangibles	$23.32M	$24.00M	$31.95M
YoY Change	-30.12%	-3.06%	191.51%
Long-Term Investments
YoY Change
Other Assets	$124.0K	$124.0K	$578.0K
YoY Change	-8.82%	31.91%	514.89%
Total Long-Term Assets	$81.36M	$84.74M	$96.31M
YoY Change	-22.67%	206.13%	594.55%
TOTAL ASSETS
Total Short-Term Assets	$188.7M	$182.2M	$123.9M
Total Long-Term Assets	$81.36M	$84.74M	$96.31M
Total Assets	$270.1M	$266.9M	$220.2M
YoY Change	26.01%	81.9%	47.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.98M	$8.902M	$12.15M
YoY Change	-18.59%	-32.07%	6.27%
Accrued Expenses	$15.39M	$20.44M	$18.68M
YoY Change	-39.01%	-4.19%	-19.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.875M	$5.000M
YoY Change
Total Short-Term Liabilities	$47.30M	$34.40M	$31.95M
YoY Change	15.47%	-2.97%	-10.69%
LONG-TERM LIABILITIES
Long-Term Debt	$42.91M	$43.94M	$0.00
YoY Change
Other Long-Term Liabilities	$700.0K	$17.50M	$22.90M
YoY Change	-96.83%	201.72%	294.83%
Total Long-Term Liabilities	$42.91M	$43.94M	$22.90M
YoY Change		657.52%	294.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.30M	$34.40M	$31.95M
Total Long-Term Liabilities	$42.91M	$43.94M	$22.90M
Total Liabilities	$90.21M	$78.33M	$54.80M
YoY Change	120.21%	90.12%	32.05%
SHAREHOLDERS EQUITY
Retained Earnings	$26.28M	$17.20M	$1.768M
YoY Change	-202.44%	-120.73%	-101.86%
Common Stock	$16.00K	$16.00K	$16.00K
YoY Change	0.0%	6.67%	6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$80.80M	$75.79M	$62.31M
YoY Change	118.35%	321.14%
Treasury Stock Shares	1.242M shares	1.150M shares	896.7K shares
Shareholders Equity	$179.1M	$171.1M	$165.4M
YoY Change
Total Liabilities & Shareholders Equity	$270.1M	$266.9M	$220.2M
YoY Change	26.01%	81.9%	47.41%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	$9.090M	$15.43M	$4.503M
YoY Change	-84.14%	29.11%	-65.62%
Depreciation, Depletion And Amortization	$950.0K	$950.0K	$940.0K
YoY Change	41.79%	163.89%	193.75%
Cash From Operating Activities	$25.92M	$7.890M	$37.55M
YoY Change	-34.48%	-40.09%	-1527.76%
INVESTING ACTIVITIES
Capital Expenditures	-$2.730M	-$1.580M	-$200.0K
YoY Change	259.21%	-88.86%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$2.730M	-$1.580M	-$200.0K
YoY Change	-90.12%	-88.86%	100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-6.080M	35.84M	-9.660M
YoY Change	-67.01%	-335.17%
NET CHANGE
Cash From Operating Activities	25.92M	7.890M	37.55M
Cash From Investing Activities	-2.730M	-1.580M	-200.0K
Cash From Financing Activities	-6.080M	35.84M	-9.660M
Net Change In Cash	17.11M	42.15M	27.69M
YoY Change	-363.64%	-359.38%	-1114.29%
FREE CASH FLOW
Cash From Operating Activities	$25.92M	$7.890M	$37.55M
Capital Expenditures	-$2.730M	-$1.580M	-$200.0K
Free Cash Flow	$28.65M	$9.470M	$37.75M
YoY Change	-28.94%	-65.37%	-1592.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14862015	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	1009183048	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2856000	USD
CY2017Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2657000	USD
CY2016Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	3528000	USD
CY2017Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	936000	USD
CY2016Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	7600000	USD
CY2017Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2389000	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments BusinessCombinationFutureConsiderationPayments	15000000	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due In Fifth Year BusinessCombinationFutureConsiderationPaymentsDueInFifthYear	0	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due In Fourth Year BusinessCombinationFutureConsiderationPaymentsDueInFourthYear	0	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due In Second Year BusinessCombinationFutureConsiderationPaymentsDueInSecondYear	0	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due In Third Year BusinessCombinationFutureConsiderationPaymentsDueInThirdYear	0	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due Next Twelve Months BusinessCombinationFutureConsiderationPaymentsDueNextTwelveMonths	15000000	USD
CY2017Q4	egrx	Business Combination Future Consideration Payments Due Thereafter BusinessCombinationFutureConsiderationPaymentsDueThereafter	0	USD
CY2017Q3	egrx	Debt Instrument Periodic Payments Percent Of Principal DebtInstrumentPeriodicPaymentsPercentOfPrincipal	0.025
CY2016Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	1643000	USD
CY2017Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	964000	USD
CY2016Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	78000	USD
CY2017Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	1172000	USD
CY2015	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	0.00
CY2016	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	0.07
CY2017	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	0.04
CY2017Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	7235000	USD
CY2015	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	323000	USD
CY2016	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	9430000	USD
CY2017	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-1993000	USD
CY2017	egrx	License Agreement Potential Milestone Payments LicenseAgreementPotentialMilestonePayments	10000000	USD
CY2017	egrx	Marketing Rights Term MarketingRightsTerm	P10Y
CY2015	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	367000	USD
CY2016	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	0	USD
CY2017	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	0	USD
CY2017Q4	egrx	Number Of Clinical Trial Sites NumberOfClinicalTrialSites	12	site
CY2017Q4	egrx	Number Of Products NumberOfProducts	5	product
CY2017Q4	egrx	Obligations Future Payments ObligationsFuturePayments	127551000	USD
CY2017Q4	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	120000	USD
CY2017Q4	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	117000	USD
CY2017Q4	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	5674000	USD
CY2017Q4	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	39145000	USD
CY2017Q4	egrx	Obligations Future Payments Due Next Twelve Months ObligationsFuturePaymentsDueNextTwelveMonths	81977000	USD
CY2017Q4	egrx	Obligations Future Payments Due Thereafter ObligationsFuturePaymentsDueThereafter	518000	USD
CY2015	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2016	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	286000	USD
CY2017	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2016Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1592000	USD
CY2017Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1369000	USD
CY2016Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	21000	USD
CY2017Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	1069000	USD
CY2017	egrx	Product Development Agreements Exclusive Rights Acquired Numberof Products ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts	33	product
CY2017	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue	10897000	USD
CY2015Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1176140	shares
CY2016Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1281208	shares
CY2017Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1349339	shares
CY2017	egrx	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	3400000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14716000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11981000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42194000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53821000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25237000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15391000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2094000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1254000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9068000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4310000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6003000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4811000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1506000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2438000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	213872000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	233639000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4051000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9768000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15429000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4051000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9768000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15429000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	222000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	948000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2815000	USD
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7235000	USD
CY2016Q4	us-gaap	Assets Assets	214320000	USD
CY2017Q4	us-gaap	Assets Assets	270060000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	109110000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	188697000	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	957000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-7377000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1012000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	15055000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22129000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	709000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34869000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79083000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52820000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114657000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44214000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26263000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	61837000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2204312	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15890862	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16089439	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7762000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	35785000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	33714000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1175000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1304000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2094000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3713000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	919000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2409000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-29553000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	18045000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	28643000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11354000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-30120000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	17289000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3109000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3050000	USD
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-30116000	USD
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	17289000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-567000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-756000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31752000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14404000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	28643000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11354000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17700000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	151000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	285000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1405000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4993000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5190000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1946000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	240000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5185000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6454000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2944000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1655000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	195000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	80000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	28000	USD
CY2015	us-gaap	Depreciation Depreciation	112000	USD
CY2016	us-gaap	Depreciation Depreciation	641000	USD
CY2017	us-gaap	Depreciation Depreciation	932000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	641000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	932000	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.75
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.24
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.50
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.44
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.80
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.52
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.96
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.27
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.52
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.29
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.25
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.79
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.05
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.10
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.10
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	23256000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	948000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3763000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	9861000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2430000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1734000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3052000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3161000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3084000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33372000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23322000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1750000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-273000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-300000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2574000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	53427000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	72945000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28026000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21002000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	482000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	2800000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	10542000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	356000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10668000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8460000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14311000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15919000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11627000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	11873000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-316000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9096000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-520000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6000000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13800000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12303000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2379000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1003627	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	900423	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	805321	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33372000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23322000	USD
CY2015	us-gaap	Interest Expense InterestExpense	11000	USD
CY2016	us-gaap	Interest Expense InterestExpense	8000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1136000	USD
CY2015	us-gaap	Interest Paid InterestPaid	11000	USD
CY2016	us-gaap	Interest Paid InterestPaid	8000	USD
CY2017	us-gaap	Interest Paid InterestPaid	651000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	708000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1698000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	2739000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5118000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1131000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2489000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	900000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	931000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	84000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	91000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	664000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214320000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270060000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40965000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47302000	USD
CY2017Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1700000	USD
CY2015	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2016	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1650000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	48750000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4875000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	5000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	38750000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5000000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	42905000	USD
CY2015	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4752000	USD
CY2016	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	14784000	USD
CY2017	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	17770000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55813000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-33670000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8104000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1881000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45800000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5186000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9718000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	53207000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	58919000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	2571000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	81453000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	51943000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-896000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	13099000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	11952000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	57298000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	81453000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	22924000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	4503000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15431000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	9085000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	51943000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	22470000	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	76000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1045000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	63667000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	136131000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	162717000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	2560000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-897000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	13656000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	12308000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	28284000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	53351000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	32696000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	5902000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	24950000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	10442000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	73990000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2494000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	670000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	120000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	117000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	395000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	674000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	518000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1688000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1423000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	355000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	561000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	136000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124000	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	45000000	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	49796000	USD
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	37500000	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	37003000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	43792000	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1192000	USD
CY2015	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2016	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	4850000	USD
CY2017	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	26860000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14250000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	750000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1881000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1590000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4436000	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	105999000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	62000000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11357000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15101000	USD
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	135000	USD
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	116000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1654000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	9597000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6500000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54331000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	50000000	USD
CY2015	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	105999000	USD
CY2016	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	62000000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1750000	USD
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1482000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3619000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4338000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4822000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9258000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3316000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6820000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	61307000	USD
CY2017Q4	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	61307000	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1250000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27855000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28289000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32607000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25659000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26284000	USD
CY2017	us-gaap	Royalty Revenue RoyaltyRevenue	153880000	USD
CY2015	us-gaap	Royalty Expense RoyaltyExpense	7885000	USD
CY2016	us-gaap	Royalty Expense RoyaltyExpense	19521000	USD
CY2017	us-gaap	Royalty Expense RoyaltyExpense	23472000	USD
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	8259000	USD
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	99040000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12968000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40646000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	45327000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	66227000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	29591000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	40918000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	37833000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	81140000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	189482000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	76793000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	50108000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	63021000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	46785000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	236707000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20165000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53329000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71416000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	4051000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	9768000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	15429000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.2840
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.3095
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.2856
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3290
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3236
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3763
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0209
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0234
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0242
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0094
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0170
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	98230	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	265784	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	792500	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	925329	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.92
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.79
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	32.83
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	54700000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	59200000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33700000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1844842	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2324918	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2786568	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.16
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.53
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.13
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	668702	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1043710	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1437229	shares
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.94
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	21.78
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	81.61
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	83.94
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	3046000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	214194	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	197895	shares
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3046000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	54331000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1482000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3619000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4338000	USD
CY2016Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	75000000.0	USD
CY2017Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	27908000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	90343000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	151226000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	179144000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	566838	shares
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1241695	shares
CY2016	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	566838	shares
CY2017	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	674857	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	37003000	USD
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	80795000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37000000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37003000	USD
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	43792000	USD
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	43800000	USD
CY2017Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1000000	USD
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16253781	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16434104	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15908211	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15250154	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15533681	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15102890	shares
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-18-000003-index-headers.html	Edgar Link	pending
0000827871-18-000003-index.html	Edgar Link	pending
0000827871-18-000003.txt	Edgar Link	pending
0000827871-18-000003-xbrl.zip	Edgar Link	pending
chart-00f04e03310c523d94b.jpg	Edgar Link	pending
egrx-20171231.xml	Edgar Link	completed
egrx-20171231.xsd	Edgar Link	pending
egrx-20171231_cal.xml	Edgar Link	unprocessable
egrx-20171231_def.xml	Edgar Link	unprocessable
egrx-20171231_lab.xml	Edgar Link	unprocessable
egrx-20171231_pre.xml	Edgar Link	unprocessable
egrx_10kx2017.htm	Edgar Link	pending
exhibit103110k2017.htm	Edgar Link	pending
exhibit103210k2017.htm	Edgar Link	pending
exhibit21110k2017.htm	Edgar Link	pending
exhibit23110k2017.htm	Edgar Link	pending
exhibit31110k2017.htm	Edgar Link	pending
exhibit31210k2017.htm	Edgar Link	pending
exhibit32110k2017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2017 Q4 Form 10-K Financial Statement

#000082787118000003 Filed on February 26, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2017 Q4 Form 10-K Financial Statement

#000082787118000003 Filed on February 26, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx